Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population

TÜREDİ S. , Cinar O., Yavuz I., MENTEŞE A. , GÜNDÜZ A. , KARAHAN S. C. , ...Daha Fazla

JOURNAL OF NEPHROLOGY, cilt.23, sa.3, ss.335-340, 2010 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Konu: 3
  • Basım Tarihi: 2010
  • Sayfa Sayıları: ss.335-340


Introduction: Conventional biomarkers suffer from the drawback of being elevated in chronic renal failure even in the absence of myocardial ischemia. Ischemia-modified albumin (IMA) is a new biomarker proposed for the diagnosis of myocardial ischemia. This study was performed with the primary aim of determining IMA levels in patients with end stage renal disease (ESRD). The secondary aim of the study was to determine the impact of hemodialysis (HD), HD speed, and hemoglobin (Hb) levels on IMA levels.